These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7902248)

  • 1. Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys.
    Boudinot FD; Schinazi RF; Doshi KJ; McClure HM; Chu CK
    Drug Metab Dispos; 1993; 21(5):855-60. PubMed ID: 7902248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral activity, biochemistry, and pharmacokinetics of 3'-azido-2',3'-dideoxy-5-methylcytidine.
    Schinazi RF; Chu CK; Eriksson BF; Sommadossi JP; Doshi KJ; Boudinot FD; Oswald B; McClure HM
    Ann N Y Acad Sci; 1990; 616():385-97. PubMed ID: 1706574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.
    Asif G; Hurwitz SJ; Gumina G; Chu CK; McClure HM; Schinazi RF
    Antimicrob Agents Chemother; 2005 Feb; 49(2):560-4. PubMed ID: 15673733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.
    Schinazi RF; Boudinot FD; Ibrahim SS; Manning C; McClure HM; Liotta DC
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2432-8. PubMed ID: 1336946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.
    Kelley JA; Litterst CL; Roth JS; Vistica DT; Poplack DG; Cooney DA; Nadkarni M; Balis FM; Broder S; Johns DG
    Drug Metab Dispos; 1987; 15(5):595-601. PubMed ID: 2891473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys.
    Boudinot FD; Schinazi RF; Gallo JM; McClure HM; Anderson DC; Doshi KJ; Kambhampathi PC; Chu CK
    AIDS Res Hum Retroviruses; 1990 Feb; 6(2):219-28. PubMed ID: 2328158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
    Frick LW; St John L; Taylor LC; Painter GR; Furman PA; Liotta DC; Furfine ES; Nelson DJ
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2285-92. PubMed ID: 8285607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.
    Ma L; Hurwitz SJ; Shi J; Mcatee JJ; Liotta DC; McClure HM; Schinazi RF
    Antimicrob Agents Chemother; 1999 Feb; 43(2):381-4. PubMed ID: 9925539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
    Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
    Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys.
    Chen H; Schinazi RF; Rajagopalan P; Gao Z; Chu CK; McClure HM; Boudinot FD
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1625-30. PubMed ID: 10606085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catabolic disposition of 3'-azido-2',3'-dideoxyuridine in hepatocytes with evidence of azido reduction being a general catabolic pathway of 3'-azido-2',3'-dideoxynucleosides.
    Cretton EM; Xie MY; Goudgaon NM; Schinazi RF; Chu CK; Sommadossi JP
    Biochem Pharmacol; 1992 Sep; 44(5):973-80. PubMed ID: 1326966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus.
    Frick LW; Lambe CU; St John L; Taylor LC; Nelson DJ
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2722-9. PubMed ID: 7695253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration.
    Melvin GC; Ellison SR; Monk CM; Bates TR
    Res Commun Chem Pathol Pharmacol; 1990 Nov; 70(2):193-204. PubMed ID: 2277865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.
    Kaul S; Shyu WC; Shukla UA; Dandekar KA; Barbhaiya RH
    Drug Metab Dispos; 1993; 21(3):447-53. PubMed ID: 8100500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion.
    Patterson TA; Binienda ZK; Lipe GW; Gillam MP; Slikker W; Sandberg JA
    Drug Metab Dispos; 1997 Apr; 25(4):453-9. PubMed ID: 9107545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat.
    Sauer JM; Smith RL; Bao J; Kattnig MJ; Kuester RK; McClure TD; Mayersohn M; Sipes IG
    Drug Metab Dispos; 1997 Jun; 25(6):732-9. PubMed ID: 9193875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.
    Klecker RW; Collins JM; Yarchoan RC; Thomas R; McAtee N; Broder S; Myers CE
    J Clin Pharmacol; 1988 Sep; 28(9):837-42. PubMed ID: 2852679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys.
    Qian M; Swagler AR; Fong KL; Crysler CS; Mehta M; Gallo JM
    Drug Metab Dispos; 1992; 20(3):396-401. PubMed ID: 1355714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys.
    Schinazi RF; Boudinot FD; Doshi KJ; McClure HM
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1214-9. PubMed ID: 2168144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.